JNJ 31020028

Catalog No.S6416 Batch:S641601

Print

Technical Data

Formula

C34H36FN5O2
Molecular Weight 565.68 CAS No. 1094873-14-9
Solubility (25°C)* In vitro DMSO 100 mg/mL (176.77 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description JNJ 31020028 is a novel neuropeptide Y Y2 receptor antagonist which bound with high affinity with human and rat Y2 receptor (pIC50=8.07±0.05 for human Y2 receptor, and pIC50=8.22±0.06 for rat Y2 receptor) and >100-fold selective versus human Y1, Y4, and Y5 receptors.
Targets
rat Y2 receptor [1] human Y2 receptor [1]
8.22(pIC50) 8.07(pIC50)
In vitro

JNJ-31020028 is assayed by binding in a panel of 50 receptors, ion channels, and transporters assays including adenosine (A1, A2A, A3), adrenergic (α1, α2, β1), angiotensin (AT1), dopamine (D1, D2), bradykinin (B2), cholecystokinin (CCKA), galanin (GAL2), melatonin (ML1), muscarinic (M1, M2, M3), neurotensin (NT1), neurokinin (NK2, NK3), opiate (μ, κ, δ), serotonin (5-HT1A, 5-HT1B, 5-HT2A, 5-HT3, 5-HT5A, 5-HT6, 5-HT7), somatostatin, vasopressin (V1a), norepinephrine transporter, dopamine transporter, and ion channels (sodium, calcium, potassium, and chloride). The Y2 antagonist at concentrations up to 10μM has no significant affinity for any receptor/transporter/ion channel (<50% inhibition at 10μM) other than the Y2 receptor. Selectivity of Y2 antagonist is further evaluated in a panel comprised of 65 kinases. JNJ-31020028 (10μM) does not inhibit any of the kinase included in the panel[1].
In vivo

In a variety of anxiety models, JNJ-31020028 is found to be ineffective, although it does block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake. JNJ-31020028 is administered to rats by the oral (10 mg/kg), intravenous (1 mg/kg), and subcutaneous (10 mg/kg) route, and pharmacokinetic parameters are determined. The compound has poor oral bioavailability (6%) but high subcutaneous bioavailability (100%). Subcutaneous dosing is the preferred route for several of the models and yields good plasma levels (Cmax 4.35 μmol/l) and fast absorption with a 0.83-h half-life. JNJ-31020028 has no significant effect on locomotor activity during the test[1].

Protocol (from reference)

Animal Study:

[1]
  • Animal Models

    male Wistar rats

  • Dosages

    1-10 mg/kg

  • Administration

    s.c.

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.